The National Institute of Allergy and Infectious Diseases has awarded a 5-year, $22 million grant to an international consortium to develop antibody-based therapies against four deadly viruses with no approved treatments or vaccines, including Crimean-Congo hemorrhagic fever and three hantaviruses.

The project was announced by Albert Einstein College of Medicine, which is part of the consortium.

 

Credit CDC

Read more…